<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01472757</url>
  </required_header>
  <id_info>
    <org_study_id>VR506/2/002</org_study_id>
    <nct_id>NCT01472757</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of Asthma</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Parallel Group, Study to Evaluate the Efficacy and Safety of VR506 Inhaled From a New Inhaler in Adolescent and Adult Subjects With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vectura Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vectura Limited</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the clinical efficacy of three doses of VR506
      delivered via a new dry powder inhaler for the treatment of asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morning Pre-Dose FEV(1)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean change from start of treatment baseline for in clinic morning pre-dose FEV(1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of VR506 in subjects with asthma</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of withdrawals due to worsening asthma and mean change in pre-dose PEF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the subjects' operation and handling of the new inhaler</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessment of the compliance with the treatment regimen and acceptability of the device by questionnaire and operation</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">374</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VR506</intervention_name>
    <description>VR506 inhalation powder delivered via a new dry powder inhaler</description>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_label>Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo delivered via a new dry powder inhaler</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Adolescents aged 12 to 17 years (inclusive) and adults aged 18 to 65 years (inclusive)

          -  Documented clinical history of asthma (i.e. made by a physician) for at least 6 months
             before the Screening Visit

          -  Documented asthma reversibility in the 5 years prior to or during Screening, or if the
             asthma reversibility criterion is not met at Screening, then a repeat test may be
             carried out at the end of the Run-In Period

          -  Subjects with asthma who, in the opinion of the investigator, require maintenance
             therapy with ICS, are believed to have been regularly compliant with this therapy, and
             are therefore likely to deteriorate within 6 weeks following withdrawal of their usual
             ICS treatment

          -  Mild or moderate asthma, defined as:

               -  Mild - good asthma control achieved by low-dose inhaled corticosteroid (daily
                  dose 200-500 μg beclomethasone dipropionate or equivalent) with or without other
                  low-intensity treatment (e.g. leukotriene modifiers or cromones) for at least 28
                  days before the Screening Visit

               -  Moderate - good asthma control achieved by low- to moderate-dose ICS (daily dose
                  200-1000 μg beclomethasone dipropionate or equivalent), and long acting
                  β2-agonist (LABA) or other extra treatment, for at least 28 days before the
                  Screening Visit

          -  Ability to use the new inhaler correctly, based on investigator's review of the
             completed inhaler operation checklist

          -  Ability to use the eDiary correctly, assessed by the investigator during the Screening
             Period

          -  Ability to perform technically satisfactory pulmonary function tests

          -  Ability to comply with study procedures, including blood sampling

          -  Body mass index (BMI) of 16.0 to 26.0 kg/m2 in adolescents, and in adult subjects
             recruited in the Philippines, and 18.0 to 32.0 kg/m2 in adults recruited in other
             countries

          -  Available to complete all study visits

          -  Oral peak inspiratory flow (PIF) of at least 60 L/min; using an appropriate device set
             to match the resistance of the nDPI

          -  Good health, except for the presence of asthma, according to medical history and
             physical examination

          -  Normal (i.e. non-clinically significant abnormality) 12-lead electrocardiogram (ECG)

          -  Negative drug, alcohol, and urine cotinine screen; subjects must test negative for
             amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, cotinine (unless
             related to nicotine-containing therapies), ethanol, and opiates (unless given as a
             prescription medicine)

          -  Non-smokers or ex-smokers with a smoking history of less than 10 pack-years (e.g. &lt;20
             cigarettes per day for 10 years or 40 cigarettes per day for 5 years) and stopped
             smoking for at least one year prior to the Screening Visit. Smoking will not be
             permitted throughout the study

          -  Female subjects of child-bearing potential must be using medically acceptable forms of
             contraception; approved forms of contraception are abstinence, hormonal (oral,
             implant, transdermal, or injection, in use for ≥3 consecutive months before the start
             of the Run-In Period), double barrier (condom with spermicide, diaphragm with
             spermicide), intrauterine device, or vasectomised partner (≥6 months since vasectomy)

        Exclusion Criteria:

          -  Regular use (≥3 times per week) of topical steroids taken to treat dermatitis,
             rhinitis or allergic conjunctivitis, within 28 days of the Screening Visit

          -  Subjects who have or who have had an upper or lower respiratory tract infection within
             28 days of the Screening Visit

          -  Subjects with asthma that required admission to an intensive care unit and/or
             ventilation within the previous 12 months

          -  History of lung cancer

          -  Subjects with &quot;brittle asthma&quot;, defined as patients with asthma who either maintain
             over many months a wide variation (&gt;40%) in PEF between morning and evening
             measurements despite moderate to high doses of ICS, or are prone to acute, severe and
             often unpredictable attacks of asthma that may be fatal, on a background of apparently
             good asthma control

          -  History or current diagnosis of human immunodeficiency virus (HIV) infection

          -  Active chronic hepatitis B or C infection. If the patient's screening test is positive
             for hepatitis B surface antigen, the patient should be excluded unless the
             investigator, after a careful review of the patient's medical history and current
             laboratory tests of liver function, can exclude the possibility of recent or current
             infection

          -  Persistent arterial hypotension, with average systolic blood pressure (SBP) readings
             of ≤95 mmHg

          -  Subjects who have any clinically significant abnormality or finding from examination,
             tests, or history that may compromise subject safety, specifically any history of
             cardiac, renal or hepatic impairment

          -  Subjects with an abnormal ECG

          -  Persistent elevation of blood pressure, with average SBP readings of ≥160 mmHg or
             average diastolic blood pressure (DBP) readings of ≥100 mmHg

          -  Pregnant or lactating females

          -  Participation in another clinical study in the 28 days prior to the Screening Visit

          -  Current or a history of drug or alcohol abuse or dependence according to World Health
             Organization criteria in the 12 months prior to the Screening Visit or evidence of
             such abuse as indicated by laboratory assays conducted during the screening evaluation

          -  Evidence of clinically significant renal, hepatic, cardiac, pulmonary (apart from
             asthma) or metabolic dysfunction, e.g. diabetes mellitus, thyrotoxicosis, uncorrected
             hypokalaemia, or predisposition to low levels of serum potassium

          -  Inability to communicate well with the investigator

          -  Evidence of clinically significant renal, hepatic, cardiac, pulmonary (apart from
             asthma) or metabolic dysfunction, e.g. diabetes mellitus, thyrotoxicosis, uncorrected
             hypokalaemia, or predisposition to low levels of serum potassium

          -  Donation of ≥450 mL of blood or blood products within the previous 12 weeks prior to
             the Screening Visit

          -  History of allergy, intolerance or contraindications to corticosteroids, lactose, or
             severe allergy to milk proteins

          -  Consumption of alcohol- or caffeine-containing foods or beverages from midnight before
             or during the Screening Visit. The visit can be rescheduled once before the subject is
             excluded

          -  History of medically diagnosed chronic respiratory diseases (other than asthma) e.g.
             chronic obstructive pulmonary disease

          -  Subjects with previously clinically or radiologically diagnosed osteoporosis and/or
             those receiving regular treatment (more than 1 month duration) with oral or parenteral
             corticosteroids in the last year prior to the Screening Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Dahl, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10038</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10031</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10044</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10022</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10014</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10027</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10033</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10016</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>90283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10023</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10001</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10025</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10041</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10011</name>
      <address>
        <city>Albany</city>
        <state>Georgia</state>
        <zip>31707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10002</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10042</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10029</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10008</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10020</name>
      <address>
        <city>Warrensburg</city>
        <state>Missouri</state>
        <zip>64093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10009</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10034</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10035</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10015</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10040</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10010</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <zip>43560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10017</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10028</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10024</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10021</name>
      <address>
        <city>Upland</city>
        <state>Pennsylvania</state>
        <zip>19013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10003</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10019</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <zip>78006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10039</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 10004</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 31001</name>
      <address>
        <city>Lipa City</city>
        <state>Batangas</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 31002</name>
      <address>
        <city>Davao City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 31003</name>
      <address>
        <city>Iloilo City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 31004</name>
      <address>
        <city>Pasig City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 31005</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 31007</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 20018</name>
      <address>
        <city>Bialystok</city>
        <zip>15-430</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 20013</name>
      <address>
        <city>Biołystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 20015</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 20019</name>
      <address>
        <city>Krakow</city>
        <zip>31-024</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 20012</name>
      <address>
        <city>Lublin</city>
        <zip>20-718</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 20008</name>
      <address>
        <city>Ostrów Wielkopolski</city>
        <zip>63-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 20003</name>
      <address>
        <city>Poznań</city>
        <zip>60-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 20005</name>
      <address>
        <city>Poznań</city>
        <zip>60-823</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 20016</name>
      <address>
        <city>Skiemiewice</city>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 20021</name>
      <address>
        <city>Tarnow</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 20010</name>
      <address>
        <city>Warszawa</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 20001</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-445</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 20006</name>
      <address>
        <city>Wrocław</city>
        <zip>53-301</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 20014</name>
      <address>
        <city>Zawadzkie</city>
        <zip>47-120</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 20007</name>
      <address>
        <city>Łodź</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 20009</name>
      <address>
        <city>Łódź</city>
        <zip>90-553</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 21002</name>
      <address>
        <city>Brasov</city>
        <zip>500086</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 21011</name>
      <address>
        <city>Bucuresti</city>
        <zip>050554</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 21004</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400217</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 21009</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400371</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 21010</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400371</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 21007</name>
      <address>
        <city>Iasi</city>
        <zip>700115</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 21008</name>
      <address>
        <city>Iasi</city>
        <zip>700870</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 21013</name>
      <address>
        <city>Judetul Cluj</city>
        <zip>400371</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 21012</name>
      <address>
        <city>Judetul Iasi</city>
        <zip>700115</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 21001</name>
      <address>
        <city>Targu-Mures</city>
        <zip>540141</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 21005</name>
      <address>
        <city>Timisoara</city>
        <zip>300689</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 23013</name>
      <address>
        <city>Donetsk</city>
        <zip>83099</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 23005</name>
      <address>
        <city>Kharkiv</city>
        <zip>61002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 23004</name>
      <address>
        <city>Kharkiv</city>
        <zip>61051</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 23010</name>
      <address>
        <city>Kharkiv</city>
        <zip>61124</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 23012</name>
      <address>
        <city>Kiev</city>
        <zip>02232</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 23002</name>
      <address>
        <city>Kiev</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 23009</name>
      <address>
        <city>Kiev</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 23011</name>
      <address>
        <city>Kiev</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 23017</name>
      <address>
        <city>Kiev</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 23001</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 23003</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 23018</name>
      <address>
        <city>Kyiv</city>
        <zip>04201</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 23007</name>
      <address>
        <city>Odesa</city>
        <zip>65031</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 23015</name>
      <address>
        <city>Simferopol</city>
        <zip>95034</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 23014</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 23008</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69063</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectura Clinical Trial Site 23016</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69118</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2011</study_first_submitted>
  <study_first_submitted_qc>November 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2011</study_first_posted>
  <disposition_first_submitted>May 9, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>May 9, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 26, 2014</disposition_first_posted>
  <last_update_submitted>May 9, 2014</last_update_submitted>
  <last_update_submitted_qc>May 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

